Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests a new subtype of alopecia, termed 'acute diffuse and total alopecia of the female scalp' (ADTAFS), characterized by acute and total hair loss in women with a favorable recovery profile.

This study observed inflammatory and granulomatous infiltration in alopecic nodules of the scalp and suggested that AANS should be considered in diagnoses of alopecic nodules.

This discussion suggests that acquired progressive kinking of hair in androgen-dependent scalp areas may indicate the early stages of androgenetic alopecia with a poor prognosis, but it offers no new clinical findings.

This study investigated the effects of Akkermansia muciniphila on testosterone-induced hair growth inhibition in mice, finding that both live and pasteurized forms significantly encouraged hair growth and increased hair follicle size and growth factor levels compared to testosterone treatment alone.

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study reports that four Indian patients with acne keloidalis nuchae also exhibited acanthosis nigricans, suggesting a potential link to metabolic syndrome, though further research is needed to confirm this association.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

Alopecia areata incognito in children can be effectively treated with triamcinolone acetonide and supplements, leading to full hair regrowth.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

AGC2-1 protein is essential for root hair growth in Arabidopsis.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

This report describes a new case of syndromic ichthyosis caused by compound heterozygous mutations in AP1B1, detailing the associated clinical features and molecular consequences in the patient.

In this study, researchers observed that a hidden scalp condition could contribute to acne keloidalis nuchae and potentially other primary cicatricial alopecias, impacting their diagnosis and treatment.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study found that adipose-derived stem cells with DKK1 knocked out using CRISPR/Cas9 promoted hair growth in an alopecia areata model more effectively than untreated stem cells, suggesting DKK1 is a potential therapeutic target for this condition.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This study observed an association between body mass index and androgenetic alopecia, with the highest prevalence occurring in individuals with a normal BMI at 34.8%.